Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EBITDA: 2016-2025

Historic EBITDA for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to -$231.8 million.

  • Summit Therapeutics' EBITDA fell 313.37% to -$231.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$922.0 million, marking a year-over-year decrease of 369.07%. This contributed to the annual value of -$221.2 million for FY2024, which is 64.07% up from last year.
  • As of Q3 2025, Summit Therapeutics' EBITDA stood at -$231.8 million, which was up 59.05% from -$565.9 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' EBITDA ranged from a high of -$17.9 million in Q4 2022 and a low of -$565.9 million during Q2 2025.
  • Its 3-year average for EBITDA is -$126.6 million, with a median of -$60.3 million in 2024.
  • Its EBITDA has fluctuated over the past 5 years, first grew by 1.31% in 2023, then slumped by 837.92% in 2025.
  • Over the past 4 years, Summit Therapeutics' EBITDA (Quarterly) stood at -$17.9 million in 2022, then tumbled by 104.93% to -$36.7 million in 2023, then tumbled by 66.74% to -$61.2 million in 2024, then tumbled by 313.37% to -$231.8 million in 2025.
  • Its last three reported values are -$231.8 million in Q3 2025, -$565.9 million for Q2 2025, and -$63.2 million during Q1 2025.